Ketotifen for MCAS: The Mast Cell Stabilizer That's Hard to Find but Worth It

Ketotifen is one of the most effective mast cell stabilizers available for MCAS, but it occupies an unusual position in the US healthcare system: it is not FDA-approved for systemic use in the United States (only as an ophthalmic solution for eye allergies), meaning it must be obtained from a compounding pharmacy with a prescription. Despite this barrier, ketotifen has become a cornerstone of MCAS management for many patients, and understanding why requires understanding how it differs from standard antihistamines.

Mechanism: More Than Just an Antihistamine

Ketotifen is classified as a second-generation H1 antihistamine, but its mechanism of action goes significantly beyond histamine blockade. It has three distinct actions relevant to MCAS:

H1 receptor antagonism. Like other antihistamines, ketotifen blocks H1 histamine receptors, reducing the effects of histamine already released by mast cells (itching, flushing, hives, nasal symptoms).

Mast cell stabilization. This is ketotifen's most distinctive feature. Ketotifen inhibits the release of mediators from mast cells — not just histamine, but also prostaglandins, leukotrienes, and other inflammatory mediators. This "upstream" effect means it reduces the total inflammatory load from mast cell activation, not just the histamine component. Standard antihistamines (cetirizine, loratadine, fexofenadine) only block histamine receptors after mediators are already released.

Inhibition of eosinophil and basophil activation. Ketotifen also reduces the activation of eosinophils and basophils, which are involved in allergic and inflammatory responses alongside mast cells.

This triple mechanism makes ketotifen significantly more effective for MCAS than standard antihistamines in many patients — it addresses the root cause (mast cell degranulation) rather than just blocking one downstream mediator.

Why It's Not Available in the US (and How to Get It)

Ketotifen was available in the US as Zaditen (oral tablets) until the manufacturer withdrew it from the US market in the 1990s, not due to safety concerns but due to commercial reasons. It remains available in Canada, Europe, and many other countries as an over-the-counter or prescription antihistamine.

In the US, patients can access ketotifen through:

Compounding pharmacies. A physician can write a prescription for compounded ketotifen capsules, which a compounding pharmacy prepares from bulk pharmaceutical-grade ketotifen. This is the most common route for US patients. The cost varies by pharmacy but is typically $30–$80 per month. Not all insurance plans cover compounded medications.

Canadian pharmacies. Ketotifen is available OTC in Canada (as Zaditen) and can be legally imported for personal use in small quantities. Some US patients order it from Canadian online pharmacies, though this involves navigating import regulations.

International travel. Patients who travel internationally sometimes bring back ketotifen from countries where it is available OTC.

Dosing

Oral ketotifen dosing for MCAS:

Ketotifen is typically started at a low dose in the evening due to its sedating effects, then increased gradually as tolerance develops. The full mast cell stabilizing effect may take 4–6 weeks to develop — patients should not judge efficacy too quickly.

Side Effects

Sedation. This is the most common and limiting side effect of ketotifen. It is significantly more sedating than non-sedating antihistamines like cetirizine or loratadine. Most patients find that taking it at bedtime minimizes daytime sedation, and tolerance to the sedating effect typically develops over 2–4 weeks.

Increased appetite and weight gain. Ketotifen stimulates appetite through antihistaminergic effects on the hypothalamus. This is a known and common side effect, particularly at higher doses. Some MCAS patients find this beneficial if they have had appetite suppression from their condition; others find it problematic.

Dry mouth, urinary retention, constipation. Anticholinergic effects are mild but present, particularly at higher doses.

Thrombocytopenia (rare). A rare but documented side effect is a reduction in platelet count. Periodic blood counts are recommended for patients on long-term ketotifen.

Ketotifen vs. Cromolyn Sodium

Both ketotifen and cromolyn sodium are mast cell stabilizers used for MCAS, but they differ in important ways:

Many MCAS patients use both ketotifen (for systemic symptoms) and cromolyn sodium (for GI symptoms) as complementary treatments. Ketotifen is generally considered the more potent systemic mast cell stabilizer, while cromolyn is preferred for patients whose symptoms are primarily GI.

Who Benefits Most from Ketotifen

Ketotifen is most effective for MCAS patients with:

• Systemic symptoms (flushing, hives, anaphylaxis, cardiovascular symptoms) that are not adequately controlled by antihistamines alone
• GI symptoms that are not adequately controlled by cromolyn sodium
• Patients who have failed or had inadequate response to standard H1/H2 antihistamine combinations
• Patients who can tolerate the sedating effects (or who find the sedation beneficial for sleep)

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.